This section provides news and developments at member companies.
Immix Therapies Enhance Apoptotic Activity of FDA-Approved Agents by 5X and Catalyze Total Shift in Tumor Micro-Environment Immix Biopharma, Inc., a Los Angeles-based clinical-stage biopharmeceutical company developing therapies for high unmet medical […]
CEL-SCI Corporation recently announced that no further patient enrollment is required in the pivotal Phase 3 head and neck cancer study of its investigational immunotherapy, Multikine. The accrual and treatment phases of […]
TapImmune Inc., a Florida-based leading clinical-stage immuno-oncology company recently announced that it has enrolled the final patient in a randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV200 for […]
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. They currently have an innovative and […]
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, recently announced that its President and Chief […]
TapImmune (TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women’s cancers has announced that it has amended the patient inclusion criteria for its Phase 2 clinical trial of […]
Dorsey client Mayo Clinic and Cambridge, Massachusetts-based nference recently announced the formation of Qrativ. Qrativ will combine nference’s artificial intelligence (AI) knowledge synthesis platform with Mayo Clinic’s medical expertise and clinical data […]
Soligenix’s self-described “DOM–INNATE” study has initiated patient enrollment. The late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that patient […]
